Palantir Technologies has shed another 3.2% to close at $132.07, extending the post-earnings slide to a cumulative 13.2% on the week — and the question now is whether the reset is finished or still in progress.
The price action since June 3 has been relentless. From the $160.65 pre-print high, the stock has given back roughly $28 in six sessions. That move is consistent with what prior coverage flagged: two straight earnings beats followed by two straight sell-offs, both erasing pre-report run-ups almost entirely. The stock is now back to levels last seen in mid-March, and the pattern of making and then surrendering gains around catalysts is becoming the defining characteristic of the trading year. Peers have not been spared — APP fell 7.6% on the day and 14% on the week, GWRE lost 23.5%, and CGNT dropped 23.3%. The selling is broad, but Palantir's drawdown is roughly in line with the group rather than an outlier.
Options sentiment has completed its rotation from pre-print euphoria to something closer to neutral. The put/call ratio sits at 0.955 — actually a touch below its 20-day mean of 0.989 and roughly one standard deviation below it. That's the opposite of defensive: options traders are not yet paying up for downside protection despite the 13% drop. The borrow market reinforces that picture. Availability remains extraordinarily loose at 7,826% — meaning there are well over 78 shares available to borrow for every one currently lent out, a figure that has barely moved from the 8,000-9,000% range of recent weeks. Cost to borrow is a nominal 0.43%. There is no squeeze dynamic here, and no crowding in the lending market. Short interest at 3.0% of free float has crept up 3.5% on the week and 28.6% over the past month — bears are adding, but from a low base and into a frictionless borrow environment. The ORTEX short score at 32 has edged higher through the week but remains well inside moderate territory.
The Street is holding its nerve more than the price action might suggest. The most recent analyst actions — both from June 5 — were straight reiterations: Rosenblatt keeping its Buy and $225 target, Wedbush reaffirming Outperform at $230. Both targets imply 70%-plus upside from the current print. The broader analyst picture is split: the consensus sits at Hold, with a mean target of $185 against a stock trading at $132. That gap is wide, but it partly reflects RBC Capital's standing Underperform with a $90 target sitting as the bear anchor. On valuation, the reset has done some work — the P/E has compressed to 76x and EV/EBITDA to 55.5x, both down meaningfully over the past week. That is still a demanding multiple for any company, but EPS momentum scores rank in the 78th and 86th percentiles for 30- and 90-day windows, and the 90-day EPS surprise score is also in the 78th. Bulls can credibly argue the fundamentals justify a premium; the debate is about how large a premium.
Insider behaviour adds a small wrinkle. The CFO, the Chief Legal Officer, and the Chief Accounting Officer all sold in late May at prices between $135 and $160 — modestly above where the stock closed this week. The sales were modest in aggregate and appear to follow plan-based patterns given their low significance scores, but the cluster of executive selling into the pre-print strength is worth noting. The 90-day net figure is actually positive at roughly 919,000 shares net, driven by earlier activity, so the overall insider picture is not unambiguously bearish — but those May sales were timed well.
The next scheduled catalyst is the August 3 earnings report. Between now and then, the market's debate will centre on whether the current multiple — still pricing in a significant growth premium — can survive another eight weeks of macro noise without a fundamental catalyst to anchor it.
See the live data behind this article on ORTEX.
Open PLTR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
